Advent Capital Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Hold
0
142
2022
Q4
Sell
-233,351
Closed -$25.7M 128
2022
Q3
$23.9M Sell
233,351
-43,269
-16% -$4.58M 0.43% 84
2022
Q2
$28.2M Buy
276,620
+27,423
+11% +$2.99M 0.5% 76
2022
Q1
$29.1M Sell
249,197
-89,680
-26% -$10.4M 0.47% 74
2021
Q4
$38.8M Buy
+338,877
New +$38.7M 0.65% 55
2020
Q4
Sell
-265,263
Closed -$29.5M 216
2020
Q3
$29.5M Buy
265,263
+85,063
+47% +$9.53M 0.65% 61
2020
Q2
$18.9M Buy
+180,200
New +$19.3M 0.44% 72

Other funds holding BSX.PRA

Advent Capital Management's BSX.PRA Position: Q1 2023 in Review

Advent Capital Management held its Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) position steady in Q1 2023 at 0 shares worth $4.81M. The position accounts for 0.09% of the portfolio, ranked #142.

Advent Capital Management first reported a position in BSX.PRA in Q2 2020 and has held it in 6 quarters since. The position peaked at $38.8M in Q4 2021. 56 funds tracked by Wall St. Rank hold BSX.PRA as of Q1 2023.

  • Advent Capital Management held 0 shares of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A worth $4.81M as of Q1 2023.
  • Advent Capital Management left its Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A share count unchanged in Q1 2023.
  • Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A made up 0.09% of Advent Capital Management's portfolio in Q1 2023, its #142 holding.
  • Advent Capital Management first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and has held it in 6 quarters since.
  • Advent Capital Management's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $38.8M in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q1 2023.

Based on Advent Capital Management's 13F filing for Q1 2023, filed 12 May 2023.